pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Vyvgart Hytrulo
drug
save

(efgartigimod alfa + hyaluronidase (human recombinant))

Phase 3updated 6mo ago
by $ARGX ARGENX SE
Phase 3
community read0 votes

🐶 often sniffed alongside

top 3
  • tagApproval16 co-mentions · 8 sources
  • drugefgartigimod alfa16 co-mentions · 8 sources
  • drugicosapent ethyl8 co-mentions · 8 sources

all catalysts(0)

nothing on the calendar yet

News(8)

  • Argenx falls as Sjögren’s setback offsets celiac drug progress
    A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ‘blockbuster expansion opportunity’ for Vyvgart.
    biopharma_dive · 1mo ago
  • Argenx shutters Sjogren's study, losing blockbuster expansion opportunity for Vyvgart
    Argenx shares have fallen more than 13% after the surprise futility finding, which overshadowed a mid-stage celiac disease win for a separate asset acquired in the company’s $2.2 billion Forte Bios…
    biospace · 1mo ago
  • Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run
    A phase 2 celiac disease trial of argenx’s FB102 has hit its primary endpoint, delivering a boost to a drug candidate that the biotech acquired in its $2.2 billion takeover of Forte Biosciences.
    fiercebiotech · 1mo ago
  • Big Pharma-backed Nuvig halts development of lead fusion protein in rare autoimmune disease
    Big Pharma-backed Nuvig Therapeutics has halted one of the two trials for its sole clinical asset after determining the program wouldn’t be able to advance quickly enough.
    fiercebiotech · 1mo ago
  • 6 immunology targets to sustain a mammoth I&I market
    Johnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…
    biospace · 1mo ago
  • Argenx jumps on Phase 3 data for blockbuster Vyvgart
    The latest results give investors confidence in the drug's ability to be approved in another indication for which there are no approved treatments.
    biopharma_dive · 2mo ago
  • Argenx declares Phase 3 win for Vyvgart Hytrulo in autoimmune myositis
    Argenx said Monday that Vyvgart Hytrulo passed a late-stage test in a family of rare autoimmune diseases, even though the drug missed the mark in a key patient subgroup. The subcutaneous drug
    endpoints · 2mo ago
  • Argenx deepens immuno expertise with $2.2B Forte Biosciences buy
    The star of the takeover is Forte Biosciences' investigational antibody therapy, FB102, which has shown early potential in vitiligo and celiac disease.
    biospace · 3mo ago
brand
Vyvgart Hytrulo
generic
(efgartigimod alfa + hyaluronidase (human recombinant)-qvfc)
indication
Idiopathic Inflammatory Myopathy (IIM)
phase
phase_3
Data sources
ClinicalTrials.gov
last refreshed 3h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?